G. Rinaldi

发表

Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.

V. Adamo, S. Corsale, V. Agnese, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of “grading” with Ki‐67 and c‐kit immunohistochemical expressions may be a helpful tool in management of patients with flat epithelial atypia (FEA) and columnar cell lesions (CCLs) on core breast biopsy

A. Russo, V. Agnese, R. Tomasino, 2009, Journal of cellular physiology.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

P. Ascierto, A. Testori, E. Simeone, 2014, Journal of Translational Medicine.

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

Dinh Q. Phung, C. A. Shaw, M. Kumar, 2021, The Lancet Oncology.

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.

L. Mariani, S. Pilotti, G. Rinaldi, 2009, Oral oncology.

Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.

G. Rinaldi, G. Pellegriti, E. Puxeddu, 2019, European journal of cancer.

Γδ T Cell-Based Immunotherapy in Melanoma: State of the Art

F. Fulfaro, G. Rinaldi, S. Meraviglia, 2019, Journal of oncology.

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).

T. Negri, G. Rinaldi, F. Perrone, 2009, Oral oncology.

Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer.

G. Rinaldi, L. Licitra, L. Locati, 2005, Oral oncology.

Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients.

S. Ménard, G. Rinaldi, L. Licitra, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)

S. Staibano, M. Pizzichetta, I. Stanganelli, 2022, BMC cancer.

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program

L. Livi, G. Rinaldi, F. Verderame, 2022, Current oncology.

Effectiveness of clinical and instrumental follow-up for cutaneous melanoma.

G. Rinaldi, W. Mazzucco, A. Cordova, 2022, Surgical oncology.

Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience

A. Russo, G. Rinaldi, G. Novo, 2020, Oncology.

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

P. Ascierto, E. Simeone, P. Queirolo, 2014, Journal of chemotherapy.

TP53 and p16INK4A, but not H‐KI‐Ras, are involved in tumorigenesis and progression of pleomorphic adenomas

A. Russo, S. Corsale, V. Agnese, 2006, Journal of cellular physiology.

Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.

G. Altavilla, V. Adamo, A. Russo, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy

S. Pilotti, G. Rinaldi, F. Perrone, 2014, Cancer biology & therapy.

Founder mutations in BRCA1 and BRCA2 genes.

S. Cascio, E. Surmacz, V. Bazan, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses

A. Giordano, A. Russo, S. Corsale, 2007, Breast Cancer Research and Treatment.

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

F. Caponigro, R. Miceli, G. Rinaldi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

A. Giordano, A. Russo, V. Bazan, 2016, Cancer biology & therapy.

Sentinel node biopsy for malignant melanoma: a staging procedure only?

C. Liuzza, G. Rinaldi, F. Moschella, 2011, European Journal of Plastic Surgery.

Squamous Cell Tumors Recruit γδ T Cells Producing either IL17 or IFNγ Depending on the Tumor Stage

M. Todaro, G. Stassi, G. Rinaldi, 2017, Cancer Immunology Research.

Dietary restriction: could it be considered as speed bump on tumor progression road?

A. Russo, S. Vieni, V. Bazan, 2016, Tumor Biology.

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

F. Fulciniti, G. Botti, P. Ascierto, 2014, Cancer Immunology, Immunotherapy.

Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

P. Ascierto, A. Testori, E. Simeone, 2014, Cancer investigation.

A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study

L. Mainardi, F. Caponigro, G. Rinaldi, 2021, Diagnostics.

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

D. Olive, A. Russo, F. Fulfaro, 2019, Therapeutic advances in medical oncology.

Cardiotoxicity mechanisms of the combination of BRAF‐inhibitors and MEK‐inhibitors

A. Russo, G. Rinaldi, G. Bronte, 2018, Pharmacology & therapeutics.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

P. Ascierto, A. Testori, E. Simeone, 2014, Journal of Translational Medicine.

Male breast cancer: Modified radical mastectomy or breast conservation surgery? A case report and review of the literature

G. Rinaldi, A. Cordova, Matteo Rossi, 2016, International journal of surgery case reports.

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

P. Ascierto, A. Testori, P. Queirolo, 2014, Journal of experimental & clinical cancer research : CR.

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)

S. Staibano, M. Pizzichetta, I. Stanganelli, 2021, BMC Cancer.

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.

P. Ascierto, A. Testori, P. Queirolo, 2014, European journal of cancer.

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)

P. Ascierto, P. Queirolo, M. Del Vecchio, 2021, Targeted Oncology.

Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.

P. Ascierto, E. Simeone, P. Queirolo, 2013 .

Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).

P. Ascierto, A. Testori, P. Queirolo, 2013 .

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

V. Bazan, G. Rinaldi, D. Fanale, 2023, Therapeutic advances in medical oncology.

A systematic review on external ear melanoma.

G. Rinaldi, F. Moschella, A. Cordova, 2015, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Malignant metastatic melanoma to the gallbladder: Report of a peculiar case

G. Rinaldi, G. Romano, A. Agrusa, 2020, International journal of surgery case reports.

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

F. Fulciniti, G. Botti, P. Ascierto, 2014, Cancer Immunology, Immunotherapy.

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

Francesco Moschella, Paolo Li Donni, Adriana Cordova, 2012, PloS one.

Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas

G. Rinaldi, L. Licitra, P. Potepan, 2005 .

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer

F. Caponigro, L. De Cecco, S. Canevari, 2022, Cells.

Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis.

D. Schadendorf, L. Mazzucchelli, M. Mandalà, 2023, European journal of cancer.

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study

P. Queirolo, M. Del Vecchio, V. Chiarion Sileni, 2023, Cancers.

Outcomes in patients with BRAFV600–mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib

P. Ascierto, P. Queirolo, M. Del Vecchio, 2023, Tumori.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.

P. Ascierto, E. Simeone, P. Queirolo, 2023, European Journal of Cancer.

Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.

V. Adamo, S. Corsale, V. Agnese, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.

P. Ascierto, A. Testori, P. Queirolo, 2014, European journal of cancer.

A. Russo, V. Agnese, R. Tomasino, 2009, Journal of cellular physiology.

Dietary restriction: could it be considered as speed bump on tumor progression road?

A. Russo, S. Vieni, V. Bazan, 2016, Tumor Biology.

The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates

P. Ascierto, V. de Giorgi, M. Pizzichetta, 2020, BMC Cancer.

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

P. Ascierto, M. Del Vecchio, V. Chiarion-Sileni, 2023, Cancer management and research.